Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation

NCT06187311 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

940

Enrollment

OTHER

Sponsor class

Conditions

Atrial Fibrillation
Anticoagulant Adverse Reaction

Interventions

DRUG: Rivaroxaban 20 MG
DRUG: Rivaroxaban 15 MG

Sponsor

Korea University Anam Hospital